DOI : 10.1055/s-00000034

Klinische Pädiatrie

Issue 03 · Volume 226 · May 2014 DOI: 10.1055/s-004-26931


XXVII. Jahrestagung der Kind-Philipp-Stiftung für Leukämieforschung
Wilsede, Lüneburger Heide, 11. – 14. Juni 2014

Wissenschaftliche Leitung: Prof. Dr. Martin Horstmann; Prof. Dr. Martin Stanulla; Prof. Dr. Rolf Marschalek
Abstracts (HTML) List of Authors
  • A1
    Gramlich, A; Kowarz, E; Marschalek, R:

    Investigating the interplay between the Iroquois homeoprotein family and MLL or derivatives thereof

  • A15
    Schirmer, M; Queudeville, M; Trentin, L; Eckhoff, SM; Meyer, LH; Debatin, KM:

    Overcoming apoptosis resistance in high risk acute lymphoblastic leukemia by SMAC mimetics in a preclinical all xenograft model

  • A2
    Meyer, C; Marschalek, R:

    The MLL recombinome

  • A3
    Fedders, H; Zimmermann, M; Cario, G; Möricke, A; Schrappe, M; Stanulla, M:

    Prognostic impact of FLT3 gene expression and mutational status in pediatric MLL-rearranged ALL

  • A4
    Fluhr, S; Meier, A; Krombholz, CF; Niemeyer, CM; Flotho, C:

    Epigenetic changes accompany altered hemoglobin regulation in juvenile myelomonocytic leukemia

  • A5
    Schmäh, J; Müller, S; Grunz, F; Harms, H; Rotter, B; Koch, I; Kahl, G; Winter, P; Schrappe, M; Stanulla, M; Cario, G:

    Two subgroups of CRLF2-overexpressing pediatric acute lymphoblastic leukemias differ in outcome and gene expression

  • A6
    Krombholz, CF; Aumann, K; Bertele, D; Meier, A; Niemeyer, CM; Flotho, C; Erlacher, M:

    Rag2null/γcnull mice are suitable for long-term in vivo propagation of juvenile myelomonocytic leukemia

  • A7
    Torge, A; Zimmermann, M; Möricke, A; Köhler, R; Alten, J; Bartram, CR; Schrappe, M; Stanulla, M:

    Prediction of minimal residual disease in pediatric ALL: Comparison and evaluation of different mathematical methods applied to data from the ALL-BFM 2000 trial

  • A8
    Alsadeq, A; Strube, S; Krause, S; Carlet, M; Jeremias, I; Vokuhl, C; Loges, S; Aguirre-Ghiso, JA; Cario, G; Stanulla, M; Schrappe, M; Schewe, DM:

    Regulating the activity of p38α/β as a potential therapy against childhood acute lymphoblastic leukemia

  • A9
    Ponthan, F; Pal, D; Vormoor, J; Heidenreich, O:

    Establishment of a genome-wide RNAi screen; Identification of novel genes involved in clonal maintenance of ALL

  • A10
    Dagdan, E; Zaliova, M; Zimmermann, M; Dörge, P; Möricke, A; Teigler-Schlegel, A; Koehler, R; Bartram, CR; Alten, J; Schewe, D; Kratz, C; Houlston, RS; Schrappe, M; Cario, G; Stanulla, M:

    Concurrent deIetions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 (IKZF1plus) confer a very poor prognosis in pediatric acute lymphoblastic leukemia

  • A11
    Dormon, K; Heidenreich, O:

    Darwinian Evolution of Acute Lymphoblastic Leukaemia

  • A12
    McKenzie, L; Martinez-Soria, N; Bonifer, C; Heidenreich, O:

    A role for Dual Specificity Phosphatase 6 (DUSP6) in the propagation and self-renewal of Acute Myeloid Leukaemia (AML)

  • A13
    Münch, V; Hasan, N; Schirmer, M; Mirjam Eckhoff, S; Debatin, KM; Meyer, LH:

    In vivo response to remission induction poly-chemotherapy in NOD/SCID/huALL reflects patient risk and outcome

  • A14
    Martinez-Soria, N; Blair, H; Heidenreich, O:

    “In vivo” shRNA screen for the identification of the RUNX1/ETO targets with a relevance in leukaemogenesis

  • A16
    Szymansky, A; Groeneveld-Krentz, S; Hof, J; Kirschner-Schwabe, R; Eckert, C:

    Improving Diagnostic Methods for Minimal Residual Disease Detection (MRD) in Childhood Acute Lymphoblastic Leukemia (ALL)